Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.

Goldman JM, Green AR, Holyoake T, Jamieson C, Mesa R, Mughal T, Pellicano F, Perrotti D, Skoda R, Vannucchi AM.

Leukemia. 2009 Oct;23(10):1708-15. doi: 10.1038/leu.2009.142. Epub 2009 Jul 30. Review.

PMID:
19641523
2.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
3.

Kinase drug discovery approaches in chronic myeloproliferative disorders.

Kumar C, Purandare AV, Lee FY, Lorenzi MV.

Oncogene. 2009 Jun 18;28(24):2305-13. doi: 10.1038/onc.2009.107. Epub 2009 May 4. Review.

PMID:
19421140
4.

Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia.

Lin P, Jones D, Medeiros LJ, Chen W, Vega-Vazquez F, Luthra R.

Am J Clin Pathol. 2006 Oct;126(4):530-3.

PMID:
16938665
5.

New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.

Villeval JL, James C, Pisani DF, Casadevall N, Vainchenker W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):341-51. Review.

PMID:
16810610
6.

JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.

Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S.

Pathol Biol (Paris). 2011 Aug;59(4):e89-92. doi: 10.1016/j.patbio.2009.06.005. Epub 2009 Nov 24.

PMID:
19939582
8.
9.

Philadelphia chromosome-negative chronic myeloproliferative disease.

Thiele J.

Am J Clin Pathol. 2009 Aug;132(2):261-80. doi: 10.1309/AJCPR8GINMBDG9YG. Review.

PMID:
19605821
10.

[Advance of study on JAK2 V617F in myeloproliferative disorders -- review].

Xu YY, Li HM.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Feb;17(1):238-42. Review. Chinese.

PMID:
19236788
11.

Chronic myeloproliferative disorders: a tyrosine kinase tale.

De Keersmaecker K, Cools J.

Leukemia. 2006 Feb;20(2):200-5. Review.

PMID:
16341034
12.

A study of JAK2 (V617F) gene mutation in patients with chronic myeloproliferative disorders.

Hamidah NH, Farisah NR, Azlinda AB, Wong FL, Das S, Fadillah SA, Ainoon O.

Clin Ter. 2012;163(2):109-13.

PMID:
22555824
13.

The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.

Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC.

Mod Pathol. 2007 Sep;20(9):929-35. Epub 2007 Jul 20.

14.

Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.

Panani AD.

Cancer Lett. 2009 Oct 18;284(1):7-14. doi: 10.1016/j.canlet.2009.02.010. Epub 2009 Mar 9. Review.

PMID:
19269737
15.

Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?

Bock O, Hussein K, Kreipe H.

Curr Stem Cell Res Ther. 2007 Sep;2(3):253-63. Review.

PMID:
18220909
16.

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Moliterno AR, Williams DM, Rogers O, Spivak JL.

Blood. 2006 Dec 1;108(12):3913-5. Epub 2006 Aug 15.

17.

The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.

Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P.

Pathol Biol (Paris). 2007 Mar;55(2):85-7. Epub 2006 Aug 9.

PMID:
16901656
19.

JAK2 as a molecular marker in myeloproliferative diseases.

Mata R, Subirá D, García-Raso A, Llamas P.

Cardiovasc Hematol Agents Med Chem. 2007 Jul;5(3):198-203. Review.

PMID:
17630945
20.

Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine.

Mishcheniuk OY, Kostukevich OM, Dmytrenko IV, Sholoyko VV, Prokopenko IM, Martina ZV, Pilipenko GV, Klymenko SV.

Exp Oncol. 2013 Sep;35(3):202-6.

PMID:
24084459

Supplemental Content

Support Center